Celldex Therapeutics 3Q 2026: Revenue $0, EPS ($0.96) — 10-Q Summary
Celldex Therapeutics reported no revenue and a widened net loss of $75.56M for Q3 2026, driven by increased R&D and administrative expenses. The company's barzolvolimab drug showed positive results in Phase 3 studies for CSU, with a BLA submission expected in 2027. R&D expenses rose 7% to $67.4M, primarily for barzolvolimab development.
How this was made
The 30-second read
Why it matters
The earnings miss and expanded loss are likely to trigger a sell‑off, though the positive trial outcomes may provide a catalyst for future upside.
Market read
Primary earnings disclosure for a US‑listed biotech; material for traders focused on biotech earnings and pipeline news.
What to watch
R&D spend increase is primarily for barzolvolimab, which could become a revenue driver if approved.
Background
The article summarizes Celldex Therapeutics' 10‑Q filing for Q3 2026, highlighting financials and trial progress.
Ticker impact
Celldex Therapeutics reported zero revenue and a widened net loss of $75.6M in Q3 2026, with Phase 3 barzolvolimab trials meeting endpoints.
downward pressure as the market prices in the widened loss and lack of revenue
First‑report quarterly results show no revenue and a larger loss than a year ago, which is material for a biotech.
Market effects
May weigh on other early‑stage biotech stocks awaiting trial data.
Limited to US biotech sector.
Low global impact beyond biotech investors.
Counterpoint
If the Phase 3 data translate into a BLA in 2027, the long‑term upside could offset short‑term loss concerns.
Key entities
- companyCelldex Therapeutics, Inc.
Biotech firm developing barzolvolimab.
